Diabetes and Hypertension: An International Health Challenge for 2022-24
Diabetes: Global Challenge
##doi.readerDisplayName##:
https://doi.org/10.1000/zfbydj72要旨
Diabetes and hypertension are known to be major risk factors for kidney failure, cardiovascular disease and early death among the most common non-communicable diseases in the world. These two conditions have become more common in recent years in low- and middle-income countries, including Iran. This article analyses scientific data for the period 2022-2024 to investigate the causes of the rise in diabetes and hypertension, their interactions and the treatment options to reduce the global burden. The results show that the main causes of the epidemic are changes in lifestyles, the rise in obesity and poor access to health services. Prevention and control of these diseases also depend heavily on the integration of public education and health care systems. Chronic diseases such as diabetes and hypertension are a major challenge to global health. In addition to being a threat to health, they are closely linked and increase the risk of complications such as stroke, kidney failure and cardiovascular disease. Diabetes and hypertension have become much more common in Iran and worldwide in recent years, and in 2022-2024, they were identified as the leading cause of death and disability in several communities. The World Health Organization (WHO) estimates that by 2045, 700 million people worldwide will have diabetes, up from the current 422 million (WHO, 2021). Similarly, more than 1 in 13 people worldwide have hypertension, a major risk factor for cardiovascular disease (NCD Risk Factor Collaboration, 2017). The frequent occurrence of these two conditions increases the likelihood of serious complications
ダウンロード数
参考文献
American Diabetes Association. (2021). Standards of medical care in diabetes—2021. Diabetes Care, 44(Suppl. 1), S1–S232. https://doi.org/10.2337/dc21-S001
American Diabetes Association. (2023). Pathogenesis of type 1 diabetes: A comprehensive review. Diabetes, 72(1), 1–15.
American Diabetes Association. (2023). Pathophysiology of type 2 diabetes and hypertension. Diabetes Care, 46(1), 1–12.
American Diabetes Association. (2023). Standards of medical care in diabetes – 2023. Diabetes Care, 46(Suppl. 1), S1–S291.
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2021). Type 1 diabetes: Pathogenesis and prevention. The Lancet, 398(10295), 209–222. https://doi.org/10.1016/S0140-6736(21)00232-3
Azizi, F., Ghanbarian, A., & Momenan, A. A. (2022). Salt intake and hypertension in the Middle East: A systematic review. Hypertension Research, 45(6), 987–996. https://doi.org/10.1038/s41440-022-00889-3
Esteghamati, A., Meysamie, A., Khalilzadeh, O., Rashidi, A., Haghazali, M., Asgari, F., & Noshad, S. (2023). The double burden of diabetes and hypertension in Iran: A population-based study. Journal of Endocrinology and Metabolism, 25(2), 112–120.
Global Burden of Disease Study. (2023). Burden of hypertension and diabetes. Institute for Health Metrics and Evaluation (IHME).
International Diabetes Federation. (2021). IDF diabetes atlas (10th ed.). https://www.diabetesatlas.org
International Diabetes Federation. (2023). Diabetes atlas (10th ed.). https://www.diabetesatlas.org
Khardori, R., Al-Ramadhani, S., & Al-Daghri, N. (2022). Genetic and environmental triggers of type 1 diabetes in the Middle East. Journal of Autoimmunity, 130, 102845. https://doi.org/10.1016/j.jaut.2022.102845
Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393–403. https://doi.org/10.1056/NEJMoa012512
Klonoff, D. C., Ahn, D., & Drincic, A. (2018). Continuous glucose monitoring: A review of the technology and clinical use. Diabetes Technology & Therapeutics, 20(S2), S2-3–S2-12. https://doi.org/10.1089/dia.2018.0118
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Annals of Internal Medicine, 151(4), W65–W94. https://doi.org/10.7326/0003-4819-151-4-200908180-00136
Marmot, M., Allen, J., Boyce, T., Goldblatt, P., & Morrison, J. (2020). Social determinants of health and non-communicable diseases. The Lancet, 395(10224), 591–592. https://doi.org/10.1016/S0140-6736(20)30235-8
Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. Nature Reviews Nephrology, 16(4), 223–237. https://doi.org/10.1038/s41581-019-0244-2
Mills, K. T., Stefanescu, A., Bundy, J. D., Swaminathan, S., Singh, R., Stamler, J., & He, J. (2021). Global disparities of hypertension prevalence and control: A pooled analysis of 1.2 million participants from 90 countries. The Lancet, 398(10304), 957–980. https://doi.org/10.1016/S0140-6736(21)01330-1
NCD Risk Factor Collaboration. (2017). Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants. The Lancet, 389(10064), 37–55. https://doi.org/10.1016/S0140-6736(16)31919-5
NCD Risk Factor Collaboration. (2023). Worldwide trends in hypertension prevalence: 1990–2023. The Lancet, 401(10378), 733–747. https://doi.org/10.1016/S0140-6736(22)02603-2
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Welch, V. A. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Sowers, J. R., Epstein, M., & Frohlich, E. D. (2001). Diabetes, hypertension, and cardiovascular disease: An update. Hypertension, 37(4), 1053–1059. https://doi.org/10.1161/01.HYP.37.4.1053
Sowers, J. R., Epstein, M., & Frohlich, E. D. (2021). Diabetes, hypertension, and cardiovascular disease: Clinical insights. Journal of Clinical Hypertension, 23(5), 871–878. https://doi.org/10.1111/jch.14235
Tehran Lipid and Glucose Study. (2022). Prevalence of diabetes and hypertension in Iran. Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences.
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M., Kjeldsen, S. E., Kreutz, R., Laurent, S., … Zeller, T. (2023). ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 44(3), 181–270. https://doi.org/10.1093/eurheartj/ehac307
Williams, B., Poulter, N. R., Brown, M. J., Davis, B. R., Sever, P. S., & Thom, S. M. (2023). Hypertension in patients with diabetes: Mechanisms and management. The Lancet, 401(10375), 489–501. https://doi.org/10.1016/S0140-6736(22)02485-9
World Health Organization. (2021). Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes
World Health Organization. (2023). Global report on diabetes and hypertension. World Health Organization.
World Health Organization. (2023). Global status report on noncommunicable diseases 2023. World Health Organization.
World Health Organization. (2023). Global guideline for diabetes and hypertension management. World Health Organization.
World Health Organization. (2023). Global report on noncommunicable disease risk factors. World Health Organization.
World Heart Federation. (2023). Hypertension and cardiovascular disease. https://world-heart-federation.org
Zinman, B., Inzucchi, S. E., Lachin, J. M., Wanner, C., Ferrannini, E., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Pfarr, E. (2021). Cardiovascular outcomes in patients with type 2 diabetes and hypertension. New England Journal of Medicine, 385(10), 923–934. https://doi.org/10.1056/NEJMoa2103118
ダウンロード
発行日
ライセンス
コピーライト (c) 2025 Creative Commons Attribution-NonCommercial 4.0 International License
この資料のライセンスは Creative Commons 表示 - 非営利 - 改変禁止 4.0 国際 です。
This open-access journal is published under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License which permits Share (copy and redistribute the material in any medium or format) and Adapt (remix, transform, and build upon the material) under the Attribution-NonCommercial term
引用方法
##plugins.generic.shariff.share##
